RAS/MAPK pathway mutations show association with adverse survival outcomes in myelofibrosis
Last Updated: Friday, July 24, 2020
Abstract data presented during the virtual 2020 European Hematology Association Annual Congress demonstrated an association between inferior survival outcomes and adverse phenotypic features among patients with RAS/MAPK pathway mutation (RASMT)–positive (ie, NRAS, KRAS or CBL) myelofibrosis (MF). Additionally, patients with mutations in the RAS/MAPK pathway had an inferior response to JAK inhibitors. The median survival for patients with RASMT-positive MF treated with a JAK2 inhibitor was 30 months vs 91 months for patients without RASMT (HR, 4.6; 95% CI, 2.0-10.6; P =.0001).
Advertisement
News & Literature Highlights